##plugins.themes.academic_pro.article.main##

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease predominantly affecting women in the childbearing period. The majority of the pathology in SLE is related to deposits of immune complexes in various organs, which trigger complement and other mediators of inflammation. SLE is characterized by a very large spectrum of clinical manifestations accompanied by prototypic abnormalities of the immune system. Methods: This study was conducted on thirty SLE patients who were diagnosed according to the American College of Rheumatology (ACR) revised criteria. The patient was selected from the outpatient clinic of Rheumatology and Rehabilitation of Ain Shams University Hospital. Fifteen subjects, matched for age and sex, were included in the study and served as a control group. Comparison of quantitative variables between the study groups was done using the Kruskal Wallis analysis of variance (ANOVA) test with Mann Whitney U test for independent samples as posthoc multiple 2-group comparisons. A probability value (p-value) less than 0.05 was considered statistically significant. All statistical calculations were done using computer programs Microsoft Excel 2007 (Microsoft Corporation, NY, USA) and SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Results and Discussion: Our results come in agreement with the study done by Farzaneh and his colleagues in 2013, who studied fifty-two lupus patients; urinary lipocalin-2 levels in LN patients were significantly higher than those in non-LN patients. Also, our results were in accordance with the study done by Hammad, who studied 33 children with active SLE (22 with and 11 without LN) and compared them with 15 matched controls. Levels of urinary NGAL were higher in patients with LN than those without LN. These findings come in consistent with previous work done by Youssef and his co-worker in 2015, who studied 44 SLE patients and divided them into two groups, group I (twenty-two patients with LN) and group II (twenty-two patients without LN), the urinary lipocalin-2 had the highest mean levels in LN patients (group I) compared to group II and controls with a statistically significant difference. Also, between SLE patients without nephritis (group II) and controls. Conclusions: In this study, urinary lipocalin-2 was significantly higher in the SLE patients compared to the control group, and the lupus nephritis patients, when compared to the patients with SLE without nephritis,showed significantly higher levels of urinary lipocalin-2. The significant association of the urinary lipocalin-2 with the renal SLEDAI shows that urinary lipocalin-2 can be an early biomarker to diagnose patients with lupus nephritis and to detect renal disease activity.

Keywords

Systemic lupus erythematosus urinary lipocalin-2 NGAL

##plugins.themes.academic_pro.article.details##

How to Cite
Dr. Talib Mohammed Hasan AL-Musaedi, Prof. Dr. Nahid Mounir Sherif, Prof. Dr. Neveen Mahmoud Taha Fouda, & Assist. Prof. Dr. Soha Eldessouki Ibrahim. (2023). The Value of Lipocalin-2 in Patients with Systemic Lupus Erythematosus. Texas Journal of Medical Science, 20, 80–89. https://doi.org/10.62480/tjms.2023.vol20.pp80-89

References

  1. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N: Systematic review of the epidemiology
  2. of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and
  3. mortality. Arthritis Care Res 2012, 64: 159–168.
  4. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME: The geoepidemiology of systemic lupus
  5. erythematosus [abstract]. Autoimmun Rev 2010, 9: A277-A287.
  6. Zhu TY, Tam LS, Li EK: Cost-of-illness studies in systemic lupus erythematosus: a systematic review.
  7. Arthritis Care Res (Hoboken) 2011, 63: 751–760.
  8. Ruperto N, Hanrahan LM, Alarcon GS, Belmont HM, Brey RL, Brunetta P, Buyon JP, Costner MI, Cronin
  9. ME, Dooley MA, Filocamo G, Fiorentino D, Fortin PR, Franks AG Jr, Gilkeson G, Ginzler E, Gordon C,
  10. Grossman J, Hahn B, Isenberg DA, Kalunian KC, Petri M, Sammaritano L, Sánchez-Guerrero J, Sontheimer
  11. RD, Strand V, Urowitz M, von Feldt JM, Werth VP, Merrill JT: International consensus for a definition of
  12. disease flare in lupus. Lupus 2011, 20: 453–462.
  13. Jolly M, Pickard AS, Wilke C, Mikolaitis RA, Teh LS, McElhone K, Fogg L, Block J: Lupus-specific health
  14. outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis 2010, 69: 29–33.
  15. Food & Drug Administration: Guidance for Industry: Systemic Lupus Erythematosus - Developing Medical
  16. Products for Treatment. 2010.
  17. European Medicines Agency: Guideline on Clinical Investigation of Medicinal Products for the Treatment
  18. of Systemic Lupus Erythematosus, Cutaneous Lupus and Lupus Nephritis (Draft). 2013.
  19. Gallop K, Nixon A, Swinburn P, Sterling KL, Naegeli AN, Silk ME: Development of a conceptual model of
  20. health-related quality of life for systemic lupus erythematosus (SLE) from the patient’s perspective. Lupus
  21. , 21: 934–943.
  22. Mokkink L, Terwee C, Patrick D, Alonso J, Stratford P, Knol D, Bouter L, Vet H: The COSMIN checklist
  23. for assessing the methodological quality of studies on measurement properties of health status measurement
  24. instruments: an international Delphi study. Qual Life Res 2010, 19: 539–549.
  25. Beckerman NL: Living with lupus: a qualitative report. Soc Work Health Care 2011, 50: 330–343.
  26. McElhone K, Abbott J, Gray J, Williams A, Teh LS: Patient perspective of systemic lupus erythematosus in
  27. relation to health-related quality of life concepts: a qualitative study. Lupus 2010, 19: 1640–1647.
  28. Robinson J, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B,
  29. Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M: Impact of systemic lupus
  30. erythematosus on health, family, and work: the patient perspective. Arthritis Care Res 2010, 62: 266–273.
  31. Mattsson M, Moller B, Stamm T, Gard G, Bostrom C: Uncertainty and opportunities in patients with
  32. established systemic Lupus Erythematosus: a qualitative study. Musculoskeletal Care 2012, 10: 1–12.
  33. Kosinski M, Gajria K, Fernandes AW, Cella D: Qualitative validation of the FACIT-fatigue scale in systemic
  34. lupus erythematosus. Lupus 2013, 22: 422–430.
  35. Schneider M, Schmeding A, Carnarius H, Ager M, McWade V: Systemic lupus erythematosus (SLE):
  36. understanding the burden. Value Health 2010, 13: A470.
  37. Strand V, Galateanu C, Pushparajah DS, Nikai E, Sayers J, Wood R, van Vollenhoven RF: Limitations of
  38. current treatments for systemic lupus erythematosus: a patient and physician survey. Lupus 2013, 22: 819–